Meeting
2016 Gastrointestinal Cancers Symposium
Interim results of a randomized phase II study of PEGPH20 added to nab‑paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer.
Authors
Sunil R. Hingorani
Fred Hutchinson Cancer Research Center, Seattle, WA
Sunil R. Hingorani , William Proctor Harris , Tara Elisabeth Seery , Lei Zheng , Darren Sigal , Andrew Eugene Hendifar , Fadi S. Braiteh , Mark Zalupski , Ari David Baron , Nathan Bahary , Andrea Wang-Gillam , Noelle K. LoConte , Gregory M. Springett , Paul S. Ritch , Aram F. Hezel , Wen Wee Ma , Venu Gopal Bathini , Xionghua W. Wu , Ping Jiang , Andrea J. Bullock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01839487
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 439)
DOI
10.1200/jco.2016.34.4_suppl.439
Abstract #
439
Poster Bd #
M11
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Final analysis of stage 1 data from a randomized phase II study of PEGPH20 plus nab-Paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion diagnostic assay.
First Author: Andrea J. Bullock
Poster
2019 Gastrointestinal Cancers Symposium
Plasma hyaluronan is a predictive marker for pegvorhyaluronidase alfa (PEGPH20; PVHA) response in a phase II study of pancreatic ductal adenocarcinoma (PDAC).
First Author: Darin Taverna
Poster
2015 Gastrointestinal Cancers Symposium
Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer.
First Author: Sunil R. Hingorani
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial.
First Author: Sina Buchholz